title: Phase II study of cystemustine in advanced renal cancer.
authors.forename: J
authors.initials: J
authors.lastname: Chauvergne
authors.forename: P
authors.initials: P
authors.lastname: Kerbrat
authors.forename: A
authors.initials: A
authors.lastname: Adenis
authors.forename: P
authors.initials: P
authors.lastname: Chollet
authors.forename: P
authors.initials: P
authors.lastname: Fargeot
authors.forename: E
authors.initials: E
authors.lastname: Pujade-Lauraine
authors.forename: V
authors.initials: V
authors.lastname: Dieras
authors.forename: J C
authors.initials: JC
authors.lastname: Madelmont
authors.forename: M A
authors.initials: MA
authors.lastname: Lentz
authors.forename: C
authors.initials: C
authors.lastname: Toulouse
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009607:Nitrosourea Compounds / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; C051263:N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea